Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Inherited mitochondrial genetics as a predictor of immune checkpoint inhibition efficacy in melanoma

5 Jun 2025

Abstract excerpt

Abstract Response to immune checkpoint inhibitors (ICIs) in metastatic melanoma (MM) varies among patients, and current baseline biomarkers predicting treatment outcomes are limited. As mitochondrial (MT) metabolism has emerged as an important regulator of host immune function, we explored the association of host MT genetics (MT haplogroups) with ICI efficacy in 1,225 ICI-treated patients with MM from the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer Immunotherapy and Biomarkers
Share to CAR-T cell therapy research
Share to Immunotherapy and Immune Responses

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 40473950
DOI: 10.1038/s41591-025-03699-3

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Inherited mitochondrial genetics as a predictor of immune checkpoint inhibition efficacy in melanomaPMID 40473950Read ↗

Germline variants in exonic regions have limited impact on immune checkpoint blockade clinical outcomes in advanced melanoma.Semantic proximity Read ↗

Germline variants predictive of tumor mutational burden and immune checkpoint inhibitor efficacySemantic proximity Read ↗

Clinical and Immunologic Features of Germline Pathogenic Variant-Positive Patients with Melanoma.Semantic proximity Read ↗

Biological Factors behind Melanoma Response to Immune Checkpoint Inhibitors.Semantic proximity Read ↗

MHC class I and class II genotypes are independent predictors of anti-PD1 immunotherapy response in melanomaSemantic proximity Read ↗

HYDIN mutation status as a potential predictor of immune checkpoint inhibitor efficacy in melanoma.Semantic proximity Read ↗

Germline Variation in PDCD1 Is Associated with Overall Survival in Patients with Metastatic Melanoma Treated with Anti-PD-1 MonotherapySemantic proximity Read ↗

PDCD1 Polymorphisms May Predict Response to Anti-PD-1 Blockade in Patients With Metastatic Melanoma.Semantic proximity Read ↗

Genetic determinants of immune-related adverse events in patients with melanoma receiving immune checkpoint inhibitors.Semantic proximity Read ↗

Checkpoint-blocker induced autoimmunity is associated with pretreatment T cell expression profiles and favourable outcome in melanomaSemantic proximity Read ↗

HLA Genotype is Associated With Clinical Outcomes to anti-PD1 Therapy in Advanced MelanomaSemantic proximity Read ↗

Germline genetic variation and predicting immune checkpoint inhibitor induced toxicitySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.